​News & Events - WP3

This section is dedicated to news and events related to translational medecine and biotherapy. 

WP3

DFIL2

Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes​ 
IL-2 is an inducer of regulatory T cells (Treg), a population of lymphocytes that fail to control the autoimmune destruction of beta-cells in patients with Type 1 D...
WP3

DIABIL2

European phase-II clinical trial evaluating efficacy of low dose rhIL-2 in patients with recently-diagnosed type 1 diabetes
Clinical and preclinical studies, together with supportive mechanistic da...
WP3

Lancement de l'essai MS-IL2

​​​​​​​MS-IL2 vient d'obtenir l'autorisation de l'ANSM pour étudier le potentiel thérapeutique d'IL2 à faibles doses dans la sclérose en plaques.
WP3

TRANSREG has been launched.

​TRANSREG ​​is a multicenter, uncontrolled, open-label study, comparing biological and clinical responses to the administration of low dose IL2 across 11 selected autoimmune diseases (12 patients/disease) including heumatoid arthritis,...
WP3

Impact Crohn

Impact of the Fecal Flora Transplantation on Crohn's DiseaseCrohn's disease is a chronic and relapsing inflammatory bowel disease. Many data show that the intestinal flora is involved in the disease and it has been show t...
WP3

MSIL2

Biological activity and safety of low dose IL2 in Relapsing Remitting Multiple Sclerosis​
Interleukin‐2 (IL‐2) was initially discovered and used as a stimulator of effector T lymphocytes (Teffs), but is now viewed as a very promising...
WP3

TRANSREG

​TRANSREG is a multicentric, uncontrolled, open-label study, comparing biological and clinical responses to the administration of low dose of IL-2 across 11 selected pathologies (12 patients/pathology): rheumatoid arthritis, ankylosing spondyliti...